Bioxytran, Inc.
OTC: BIXT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Platt
- Employees
- 3
- Headquarters
- Newton, United States
- IPO year
- 2010
- Market cap
- $3.2M
- Website
- https://www.bioxytraninc.com
Loading BIXT…
Loading profile data…Frequently asked questions about BIXT
What does Bioxytran, Inc. (BIXT) do?
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This...
Where does BIXT trade?
Bioxytran, Inc. (BIXT) trades on the Other OTC.
What sector is BIXT in?
Bioxytran, Inc. (BIXT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bioxytran, Inc.?
David Platt is the chief executive officer of Bioxytran, Inc. (BIXT).
Where is Bioxytran, Inc. headquartered?
Bioxytran, Inc. is headquartered in United States.
Does BIXT pay a dividend?
Bioxytran, Inc. (BIXT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BIXT go public?
Bioxytran, Inc. (BIXT) completed its initial public offering in 2010.